Trial Profile
Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA (R) (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 02 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 02 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 New trial record